Masato Goya
University of the Ryukyus
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masato Goya.
Cancer Research | 2004
Shin’ichi Miyamoto; Keiichi Yano; Seiji Sugimoto; Genichiro Ishii; Takahiro Hasebe; Yasushi Endoh; Keiji Kodama; Masato Goya; Tsutomu Chiba; Atsushi Ochiai
Matrix metalloproteinase-7 (MMP-7) secreted by cancer cells has been implicated classically in the basement membrane destruction associated with tumor cell invasion and metastasis. Recent epidemiologic studies have established a correlation between high levels of circulating insulin-like growth factor (IGF) and low levels of IGF binding protein 3 (IGFBP-3), and relative risk of developing colon, breast, prostate, and lung cancer, which are known to produce MMP-7. In this study, IGFBP-3 was assessed as a candidate for the physiologic substrate of MMP-7. MMP-7 proteolysis generated four major fragments (26 kDa, 17 kDa, 15.5 kDa, and 15.5 kDa), and two cleavage sites were identified: one at the site of hydrolysis of the K144-I145 peptide bond and one at the R95-L96 peptide bond. The former site is different from the previously reported site of cleavage of IGFBP-3 by other proteases. Addition of IGFBP-3 inhibited IGF-I-mediated IGF type 1 receptor (IGF-IR) phosphorylation and activation of the downstream molecule Akt in BALB/c 3T3 fibroblasts overexpressing human IGF-IR (3T3-IGF-IR) and in two human colon cancer cell lines (COLO201 and HT29). Coincubation of the IGF-I/IGFBP-3 complex with MMP-7 restored IGF-I-mediated IGF-IR phosphorylation and activation of Akt in these cell lines. The IGF-I signal recovered by MMP-7 protected against apoptosis induced by anoikis in 3T3-IGF-IR cells. These results indicate that MMP-7 proteolysis of IGFBP-3 plays a crucial role in regulating IGF-I bioavailability, thereby promoting cell survival. This mechanism may contribute to the tumorigenesis of MMP-7-producing IGF-IR-expressing tumors in the primary site and to organ-specific metastasis in a paracrine manner.
Cancer Research | 2004
Masato Goya; Shin’ichi Miyamoto; Kanji Nagai; Yuji Ohki; Kazuyasu Nakamura; Kenya Shitara; Hiroyuki Maeda; Takafumi Sangai; Keiji Kodama; Yasushi Endoh; Genichiro Ishii; Takahiro Hasebe; Hiroyuki Yonou; Tadashi Hatano; Yoshihide Ogawa; Atsushi Ochiai
Advanced prostate cancer frequently involves the bone that has the largest content of insulin-like growth factors (IGFs). However, the role of bone-derived IGFs in bone metastasis of prostate cancer has not been studied extensively because of the lack of a reliable animal model. Therefore, we investigated whether a novel antibody directed against human IGF-I and IGF-II (KM1468) could inhibit the development of new bone tumors and the progression of established bone tumors in nonobese diabetic/severe combined immunodeficient mice implanted with human adult bone. We first confirmed that KM1468 bound specifically to human IGF-I, human IGF-II, and mouse IGF-II but not to insulin. It also blocked autophosphorylation of the type I IGF receptor induced by the binding of IGFs in human-type I IGF receptor-overexpressing BALB/c 3T3 cells, and it inhibited the IGF-stimulated growth of MDA PCa 2b cells in vitro. Then mice were injected intraperitoneally with KM1468 once weekly for 4 weeks either immediately or 4 weeks after inoculation of MDA PCa 2b cells. KM1468 markedly and dose-dependently suppressed the development of new bone tumors and the progression of established tumor foci, as determined by histomorphometry, and it also decreased serum prostate-specific antigen levels, compared with the control. This is the first report of an IGF ligand-specific inhibitory antibody that suppresses the growth of human prostate cancer cells in human adult bone. These results indicate that the IGF signaling axis is a potential target for prevention and treatment of bone metastases arising from prostate cancer.
Clinical Cancer Research | 2005
Shin’ichi Miyamoto; Michio Nakamura; Kenya Shitara; Kazuyasu Nakamura; Yuji Ohki; Genichiro Ishii; Masato Goya; Keiji Kodama; Takafumi Sangai; Hiroyuki Maeda; Zhang Shi-chuang; Tsutomu Chiba; Atsushi Ochiai
Environmental stimuli, such as organ-specific growth factors, can influence the metastatic potential of a tumor. The liver is the main source of insulin-like growth factors (IGFs). The importance of IGF signal in hepatic metastasis has been clarified mainly by IGF-I receptor targeting strategies. This study aims to confirm these precedent reports by novel tool, neutralizing antibodies against IGFs and to show that IGFs are promising therapeutic targets for hepatic metastasis in vivo. Hepatic metastasis was induced by intrasplenic injection of human colorectal cancer cell line, HT29. The antimetastatic effects of three antibodies (anti-mouse IGF-I, anti-mouse IGF-II, and anti-human/mouse IGF-II designated KM1468) were tested singly or in combination in the early phase of metastasis. The dose escalation effect of KM1468 and its survival benefit were examined in the early and late phases of metastasis. The mechanism of IGF neutralization was investigated with immunohistochemistry. Dual neutralization of paracrine IGF-I and IGF-II showed modest additive antimetastatic effects than single neutralization of IGF-I or IGF-II. In any phase of metastasis, neutralization led to significant tumor growth inhibition and longer survival. Dose escalation of KM1468 influenced survival only in the late phase of metastasis. Apoptosis increased significantly in the antibody-treated group compared with the control group (P = 0.0025) In conclusion, IGFs are promising therapeutic targets for hepatic metastases of colorectal cancers. However, the IGF dependency is probably variable in the metastatic process.
International Journal of Urology | 2003
Kimio Sugaya; Katsumi Kadekawa; Akashi Ikehara; Tomoyuki Nakayama; Munehisa Gakiya; Fumio Nashiro; Masato Goya; Tadashi Hatano; Yoshihide Ogawa
Aim: To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH).
International Journal of Cancer | 2005
Keiji Kodama; Genichiro Ishii; Shin’ichi Miyamoto; Masato Goya; Shichuan Zhang; Takafumi Sangai; Takeshi Yoshikawa; Takahiro Hasebe; Yoshiaki Hitomi; Keisuke Izumi; Atsushi Ochiai
Adenocarcinoma of the lung is characterized by frequent aerogenous spread (AE) and advancement along the alveolar wall (BAC growth). To elucidate the mechanism of AE metastasis and BAC growth in human lung adenocarcinoma, we established an in vivo orthotopic animal model and an in vitro culture. Investigation of expression levels of integrins, laminins and Type IV collagens, which are the major regulating molecules for cell attachment and anoikis was carried out and a clear correlation between the expression level of laminin 5 (LN5) and the BAC growth was observed using an orthotopic animal model. Introduction of LN5 cDNA to A549 cells increased anoikis resistance in an expression dependent manner. Cells with LN5 overexpression resisted with anoikis after treatment with PI3K‐Akt and ERK inhibitors. The amount of phosphorylated focal adhesion kinase (FAK) was also higher in LN5 overexpressing cells. Major tyrosine residues of the EGF receptor at 1068, 1086 and 1173, except at 1148, remained phosphorylated only in the LN5 overexpressing cells even without EGF stimulation, that indicates the ligand independent activation of EGF receptor. BAC growth ratio and AE was confirmed to be significantly correlated with LN5 expression in surgically resected human lung adenocarcinomas by immunohistochemistry. Our results indicate that the activation of the EGF receptor by overexpressing LN5‐integrin‐FAK signaling pathway may play a crucial role in BAC growth and AE metastasis in human lung adenocarcinoma.
BMC Research Notes | 2014
Minoru Miyazato; Satoshi Yamashiro; Masato Goya; Hitoshi Inafuku; Akashi Ikehara; Yoshinori Oshiro; Seiichi Saito; Yukio Kuniyoshi
BackgroundRenal cell carcinoma with tumor thrombus extension into the inferior vena cava occurs in approximately 5% of cases. Despite such situations, an aggressive surgical approach is recommended. However, intraoperative prevention of pulmonary embolism by a fragmended tumor thrombus is necessary. To prevent pulmonary embolism, placement of a temporary suprarenal filter has been attempted, however, the precise placement of a temporary filter between the level of the hepatic vein and right atrium is not always easy because of its migration, tilting, and strut fracture. Here we report a method for early occlusion control of the intrapericardial inferior vena cava to prevent pulmonary embolism during nephrectomy in level II or III renal cell carcinoma tumor thrombus.Case presentationOur first case was a 37-year-old Japanese man with left renal cell carcinoma extending into the inferior vena cava below the main hepatic vein (level II) and our second was a 75-year-old Japanese man with right renal cell carcinoma extending into the retrohepatic inferior vena cava at the main hepatic vein (level III). En block resection of the kidney and the tumor thrombus was performed with the aid of partial extracorporeal circulation; the postoperative course of both patients was uneventful.ConclusionControl of intrapericardial inferior vena cava is a feasible method to prevent pulmonary embolism.
Cancer Research | 2003
Hiroyuki Yonou; Naoki Kanomata; Masato Goya; Tomoyuki Kamijo; Tomoyuki Yokose; Takahiro Hasebe; Kanji Nagai; Tadashi Hatano; Yoshihide Ogawa; Atsushi Ochiai
The Prostate | 2004
Hiroyuki Yonou; Atsushi Ochiai; Masato Goya; Naoki Kanomata; Sanehiro Hokama; Makoto Morozumi; Kimio Sugaya; Tadashi Hatano; Yoshihide Ogawa
The Prostate | 2006
Masato Goya; Genichiro Ishii; Shin’ichi Miyamoto; Takahiro Hasebe; Kanji Nagai; Hiroyuki Yonou; Tadashi Hatano; Yoshihide Ogawa; Atsushi Ochiai
Hinyokika kiyo. Acta urologica Japonica | 1999
Yonou H; Masato Goya; Minoru Miyazato; Kimio Sugaya; Tadashi Hatano; Yoshihide Ogawa